好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Investigating Barriers to Advance Care Planning in Hispanic People with Parkinson’s Disease: A Qualitative Study
Movement Disorders
P10 - Poster Session 10 (8:00 AM-9:00 AM)
16-014

To investigate barriers to advance care planning (ACP) among Hispanic people with Parkinson’s Disease (PWP).

ACP is a tool for optimizing end-of-life care and is an important aspect of healthcare for PWP. However, ACP has historically been under-utilized within the Hispanic community. Given the unique challenges in Parkinson’s disease and lack of prior studies on this intersect, we aimed to identify barriers to ACP among Hispanic PWP at our center.

We recruited Hispanic PWP and care partners from a diverse academic Movement Disorders clinic for focus groups (in-person or virtual; 5-7 participants each) or one-on-one semi-structured interviews (virtual). Sessions were in English or Spanish. Qualitative data was transcribed and translated, then analyzed via an inductive approach with NVivo 15 software using 2 independent coders.

We conducted 5 focus groups (2 in-person, 3 virtual) and 15 semi-structured interviews with a total of 47 participants, at which point data saturation was reached. We identified themes relating to (1)prior ACP experience/familiarity, (2)Parkinson’s-specific considerations, (3)cultural differences, and (4)ACP learning preferences. The results highlight less ACP exposure for individuals originating from Latin America, especially those less acclimated to U.S. culture. Among those familiar with ACP, many reported prior discussions but had not written down or formalized their thoughts. Patients with milder symptoms or newer diagnosis of Parkinson’s disease were also less likely to pursue ACP due to feelings of denial and/or desire to live in the present. There was heavy emphasis on family regarding involvement in ACP discussions and expectation of care from family members mixed with fear of overburdening them. Preferences for ACP discussion included: desire for their neurologist to initiate the conversation when appropriate, more time during doctor visits, and written materials on the topic.

These qualitative findings address an important gap in care for Hispanic PWP and identify potential avenues for intervention.

Authors/Disclosures
Monica Abou-Ezzi
PRESENTER
Ms. Abou-Ezzi has nothing to disclose.
Taylor Peabody, MD Dr. Peabody has nothing to disclose.
Alberto Cruz (University of Miami) Alberto Cruz has nothing to disclose.
Lucila Hernandez (University of Miami) Lucila Hernandez has nothing to disclose.
Henry P. Moore, MD (University of Miami - Miller School of Medicine) Dr. Moore has received personal compensation in the range of $0-$499 for serving as a Consultant for Abbvie. Dr. Moore has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen Pharma. The institution of Dr. Moore has received research support from Sage Therapeutics. The institution of Dr. Moore has received research support from Bukwang Pharmaceutical. The institution of Dr. Moore has received research support from Neurocrine. The institution of Dr. Moore has received research support from CDHI Foundation. The institution of Dr. Moore has received research support from MODUS Outcomes LLC. The institution of Dr. Moore has received research support from University of Kansas Center for Research.
Silvia Vargas Parra (University of Miami) Silvia Vargas Parra has nothing to disclose.
Danielle S. Shpiner, MD An immediate family member of Dr. Shpiner has received personal compensation for serving as an employee of University of Miami. Dr. Shpiner has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Mission MSA. The institution of Dr. Shpiner has received research support from American Parkinson's Disease Association. The institution of Dr. Shpiner has received research support from CurePSP. The institution of Dr. Shpiner has received research support from Parkinson's Foundation. Dr. Shpiner has a non-compensated relationship as a COE Medical Director with Parkinson's Foundation that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Medtronic that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Boston Scientific that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Abbott that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Abbvie that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Ipsen that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Amneal that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Michael J. Fox Foundation that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a CoC Medical Director with CurePSP that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a COE Medical Director with Mission MSA that is relevant to AAN interests or activities. Dr. Shpiner has a non-compensated relationship as a Fellowship Co-Director with Merz that is relevant to AAN interests or activities.